Price T Rowe Associates Inc. MD Buys 3,950 Shares of Artivion, Inc. (NYSE:AORT)

Price T Rowe Associates Inc. MD grew its stake in shares of Artivion, Inc. (NYSE:AORT) by 11.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,489 shares of the company’s stock after acquiring an additional 3,950 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Artivion were worth $1,129,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Barclays PLC increased its stake in Artivion by 346.3% during the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after purchasing an additional 54,996 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Artivion by 14.4% during the third quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock valued at $553,000 after acquiring an additional 2,663 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after acquiring an additional 78,120 shares during the last quarter. GAMMA Investing LLC lifted its position in Artivion by 21.8% in the 4th quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock valued at $79,000 after acquiring an additional 497 shares in the last quarter. Finally, KBC Group NV boosted its stake in Artivion by 80.4% during the 4th quarter. KBC Group NV now owns 2,813 shares of the company’s stock valued at $80,000 after purchasing an additional 1,254 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Price Performance

Shares of NYSE:AORT opened at $28.98 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.24 billion, a PE ratio of -1,449.00 and a beta of 1.54. The firm’s 50 day moving average price is $24.16 and its 200-day moving average price is $27.22. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $32.33.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $98.98 million for the quarter, compared to analysts’ expectations of $94.81 million. Equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AORT. Citizens Jmp upgraded Artivion to a “strong-buy” rating in a research note on Tuesday. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of Artivion in a report on Tuesday. Finally, JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Artivion currently has an average rating of “Buy” and an average target price of $31.40.

Insider Buying and Selling at Artivion

In related news, SVP Jean F. Holloway sold 5,335 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the sale, the senior vice president now owns 149,799 shares in the company, valued at approximately $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Lance A. Berry sold 3,259 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $89,003.29. Following the completion of the transaction, the chief financial officer now directly owns 75,805 shares in the company, valued at $2,070,234.55. This trade represents a 4.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,799 shares of company stock valued at $2,356,223. Company insiders own 7.60% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.